Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled trial of OT202 eye drops in moderate-to-severe dry eye
CTR20223244Phase 2Completed
- Sponsor
- Ocumension Biotech
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OT-202 in dry eye syndrome (DED) (3 arms), sponsored by Ocumension Biotech. Primary endpoint: Change in total corneal staining score (TCSS) from baseline at Day 56 vs vehicle. Started Dec 2022; status: completed.
02
Drugs
OT-202
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20223244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223244.